Isabel Gomez de Coppel

Isabel Gomez de Coppel

Director/Board Member at NeuroCytonix, Inc.

5 connections
Health Technology

Profile

Isabel Gomez de Coppel currently works at NeuroCytonix, Inc., as Director.

Isabel Gomez de Coppel active positions

CompaniesPositionStart
NeuroCytonix, Inc.
Logo NeuroCytonix, Inc.

NeuroCytonix, Inc.

BiotechnologyHealth Technology

NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO.

 Director/Board Member -
All active positions of Isabel Gomez de Coppel

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Isabel Gomez de Coppel's experience

Connections

5

1st degree connections

1

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies1
NeuroCytonix, Inc.
Logo NeuroCytonix, Inc.

NeuroCytonix, Inc.

BiotechnologyHealth Technology

NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO.

Health Technology

See company connections
  1. Stock Market
  2. Insiders
  3. Isabel Gomez de Coppel